18F-DCFPyL PET/CT 用于初诊及生化复发前列腺癌:经病理证实的前瞻性试验
这项前瞻性试验纳入92例初诊高危前列腺癌和92例生化复发且常规CT和/或骨扫描阴性的患者,对DCFPyL PET/CT显示的疑似远处转移或复发灶进行活检。初诊组活检阳性率为74%(17/23),生化复发组为89%(33/37),但存在DCFPyL假阳性,尤其位于肋骨和骨盆。
要点
- 初诊高危前列腺癌DCFPyL PET/CT疑似远处转移灶活检阳性率为74%。
- 生化复发患者DCFPyL PET/CT疑似复发灶活检阳性率为89%。
- 肋骨或骨盆孤立性DCFPyL摄取不应假定为恶性,治疗决策前可能仍需活检。
核心结论
- DCFPyL PET/CT对初诊前列腺癌远处转移(74%)和生化复发患者复发部位(89%)具有高的活检证实阳性预测值,但存在DCFPyL-avid假阳性发现(尤其是肋骨和骨盆)。
研究设计与样本
- 前瞻性试验纳入2021年1月至12月间92例初诊高危前列腺癌患者(样本1)和92例生化复发且常规CT和/或骨扫描阴性的前列腺癌患者(样本2),均行DCFPyL PET/CT,对疑似远处转移和/或复发灶进行活检并计算阳性预测值。
诊断标准与关键数值
- 样本1中25/92例(27%)显示疑似远处转移的DCFPyL-avid病灶,23/25例(92%)接受活检,17/23例(74%)恶性、6例(26%)良性;6例良性中3例为孤立肋骨灶、3例为孤立骨盆骨灶。样本2中57/92例(62%)显示疑似复发的DCFPyL-avid病灶,37/57例(65%)接受活检,33/37例(89%)恶性、4例(11%)良性;4例良性中2例为亚厘米盆腔淋巴结和/或结节、1例为肋骨、1例为骨盆骨灶。
临床应用与阅片要点
- 作者指出肋骨和骨盆的孤立性DCFPyL摄取不应被假定为恶性,治疗决策前可能仍需活检。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Prostate-specific membrane antigen (PSMA) PET is standard for newly diagnosed high-risk and biochemically recurrent (BCR) prostate cancer. Although studies suggest high specificity of 2-(3-{1-carboxy-5-[(6-[(18)F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (DCFPyL) for targeting PSMA, false-positive findings have been identified and most studies lack histologic confirmation of malignancy. Purpose To estimate the positive predictive value (PPV) of DCFPyL PET/CT by providing histopathologic proof for DCFPyL-avid lesions suspected of being distant metastases at initial diagnosis and recurrence in BCR prostate cancer. Materials and Methods In this prospective trial, men with newly diagnosed high-risk prostate cancer (sample 1) or BCR prostate cancer and negative findings at conventional CT and/or bone scanning (sample 2) were enrolled between January and December 2021. All men underwent DCFPyL PET/CT. Suspected distant metastases and/or recurrences were biopsied. PPV was calculated. Results A total of 92 men with newly diagnosed prostate cancer (median age, 70 years; IQR, 64-75 years) (sample 1) and 92 men with BCR prostate cancer (median age, 71 years; IQR, 66-75 years) (sample 2) were enrolled. In sample 1, 25 of the 92 men (27%) demonstrated DCFPyL-avid lesions suspicious for distant metastases. Biopsy was performed in 23 of the 25 men (92%), with 17 of the 23 (74%) biopsies positive for malignancy and six (26%) benign. Of the six benign biopsies, three were solitary rib foci and three were solitary pelvic bone foci. In sample 2, 57 of the 92 men (62%) demonstrated DCFPyL-avid lesions suspicious for recurrence. Biopsy was performed in 37 of the 57 men (65%), with 33 of the 37 (89%) biopsies positive for malignancy and four (11%) benign. Of the four benign biopsies, two were subcentimeter pelvic nodes and/or nodules, one was a rib, and one was a pelvic bone focus. Conclusion PET/CT with 2-(3-{1-carboxy-5-[(6-[(18)F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid (DCFPyL) had a high biopsy-proven positive predictive value for distant metastases in newly diagnosed prostate cancer (74%) and for recurrence sites in men with biochemical recurrence (89%). However, there were DCFPyL-avid false-positive findings (particularly in ribs and pelvic bones). Solitary DCFPyL avidity in these locations should not be presumed as malignant. Biopsy may still be needed prior to therapy decisions. ClinicalTrials.gov registration no. NCT04700332 © RSNA, 2022 See also the editorial by Zukotynski and Kuo in this issue.
引用
- Ulaner, Thomsen, Bassett, et al. 18F-DCFPyL PET/CT for Initially Diagnosed and Biochemically Recurrent Prostate Cancer: Prospective Trial with Pathologic Confirmation. Radiology. 2022. PMID: 35852431. doi:10.1148/radiol.220218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。